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Stereotactic body radiotherapy (SBRT) is an effective treat-ment for early-stage inoperable non–small-cell lung can-
cer (NSCLC) with local control rates approaching 90% and 
acceptable rates of acute toxicity.1 However, one of the trade-
offs of larger fraction sizes utilized is an increased risk of 
long-term toxicity to organs-at-risk, such as the lungs, central 
airway/bronchi, esophagus, heart, great vessels, spinal cord, 
brachial plexus, and chest wall.2 Here, we report a case of 
vocal cord paralysis secondary to recurrent laryngeal nerve 
compression from radiation-induced fibrosis in a patient who 
received SBRT to a dose of 48 Gy in four fractions, 2 years 
and 9 months earlier.
CASE REPORT
An 85-year-old female with a 50+ pack-year smoking 
history was found to have a 3.3 cm left upper lobe lesion and 
a 0.8 cm right middle lobe lesion on chest computed tomogra-
phy (CT). Positron emission tomography/CT demonstrated no 
evidence of metastatic disease. CT-guided biopsies, demon-
strated TTF-1-positive adenocarcinoma. She was not a surgi-
cal candidate secondary to poor pulmonary function.
The patient was treated with SBRT to both lesions con-
secutively to a dose of 4800 cGy in four fractions treated every 
other day utilizing a 6-field fixed-angle intensity modulated 
radiotherapy plan. Daily 2DkV and cone beam CT images 
were obtained before each treatment, and typical normal tissue 
constraints were observed (Fig. 1A,B). The patient tolerated 
treatment without any significant toxicity. Routine follow-up 
did not reveal any late toxicity and surveillance CT imag-
ing demonstrated stable post-treatment changes. Recently, 2 
years and 9 months after treatment, the patient experienced 
new-onset hoarseness. Flexible laryngoscopy revealed total 
paralysis of the left vocal cord in the paramedian position. A 
repeat CT scan again demonstrated a stable 4.7 × 2.2 cm mass-
like consolidation in the left upper lobe corresponding to the 
patient’s treatment field (Fig. 1C,D).
DISCUSSION
One particular challenge with any emerging treatment 
modality is successfully defining organs-at-risk. Early experi-
ence revealed an unexpected 11-fold increased risk of grade 
3–5 toxicity for tumors within 2 cm of the main tracheobron-
chial tree.2 Similarly, the importance of limiting chest wall 
dose was elucidated only after initial cases of chest wall pain 
and rib fracture after SBRT were reported.3 Although sensory 
deficits (e.g., brachial plexopathy and chest wall pain) are rec-
ognized concerns when irradiating apical tumors, other forms 
of peripheral nerve damage, such as motor dysfunction, are 
less common.4 The time course for radiation-induced damage 
to the recurrent laryngeal nerve after conventionally fraction-
ated radiation is known to be highly variable and can occur 
up to 25 years after treatment.5 This report of left recurrent 
laryngeal nerve damage occurring more than 2.5 years after 
SBRT highlights the importance of close long-term follow-up 
of patients treated with SBRT and the ongoing need to docu-
ment and report unexpected toxicities to minimize their prob-
ability in the future. The optimal risk-adapted fractionation 
schemes for SBRT to centrally located lung tumors is currently 
being investigated by RTOG 0813. (http://www.rtog.org/
ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0813).
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FIGURE 1.  Axial and coronal CT 
images showing the patient’s left 
apical tumor obtained at simulation 
with the dose colorwash overlaid (A, 
B) and the patient’s follow-up scan 
obtained 2 years, 9 months later 
demonstrating post-radiation fibro-
sis exerting mass effect upon the 
course of the left recurrent laryngeal 
nerve with the 36 Gy isodose line 
in magenta and the area of fibrosis 
outlined in cyan (C, D).
